Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27783058 | 0.83 | MAP4K4 (0.55) | MAP4K4ALDH1A1 | |
| SCHEMBL14988250 | 0.80 | MAOA (0.50) | KDM1AMAOBMAP4K4ALDH1A1KMO | |
| SCHEMBL14988146 | 0.80 | DHFR (0.45) | KDM1AMAOBMAP4K4DHFRTDO2 | |
| SCHEMBL17860701 | 0.79 | KDM1A (0.54) | KDM1AMAOBMAP4K4DHFRIDO1 | |
| SCHEMBL10264655 | 0.79 | CYP3A4 (0.54) | KDM1AMAOBMAP4K4IDO1ALDH1A1 | |
| SCHEMBL31689000 | 0.79 | KDM1A (0.54) | KDM1AMAOBMAP4K4DHFRIDO1 | |
| SCHEMBL2318238 | 0.79 | HPGDS (0.60) | MAP4K4IDO1KMO | |
| SCHEMBL14988681 | 0.79 | KDM1A (0.61) | KDM1AMAP4K4IDO1ADORA1ALDH1A1 | |
| SCHEMBL5318865 | 0.79 | KDM1A (0.50) | KDM1AMAOBMAP4K4DHFRIDO1 | |
| SCHEMBL2131570 | 0.78 | DHFR (0.51) | KDM1AMAOBMAP4K4DHFRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434245-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-06 | — | — | US | disclosed |
| US-11434245-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-06 | — | — | US | disclosed |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-18 | — | — | US | disclosed |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-18 | — | — | US | disclosed |
| US-10870653-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-22 | — | — | US | disclosed |
| US-10870653-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-22 | — | — | US | disclosed |
| US-20190185478-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-06-20 | — | — | US | disclosed |
| US-10189842-B2 | Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-29 | — | — | US | disclosed |
| US-10189842-B2 | Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-29 | — | — | US | disclosed |
| EP-3042658-B1 | MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE | UNIV KYOTO (JP) | 2019-01-16 | — | — | EP | disclosed |
| WO-2015094119-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-25 | — | — | WO | disclosed |
| US-8785445-B2 | 7-phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | KYOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2623494-A1 | AGENT FOR TREATMENT OF EYE DISEASES | Daito Chemix Corporation (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
| CN-102325767-A | 7-phenoxy chroman carboxylic acid derivative | ARRAY BIOPHARMA INC | 2012-01-18 | — | — | CN | disclosed |
| EP-2379535-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010075200-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185478-A1 | WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | KDM1A 3768/4885MAOB 1751/4885MAP4K4 2438/4885 |
| US-10189842-B2 | Wnt pathway modulators | WNT1, WNT3A, WNT3 | KDM1A 3152/4885MAOB 2860/4885MAP4K4 742/4885 |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | PDE6A, ALDH1A2, PDE6D | KDM1A 2973/4885MAOB 1909/4885MAP4K4 3864/4885 |
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | KDM1A 1691/4885MAOB 2080/4885MAP4K4 3988/4885 |
| US-11434245-B2 | WNT pathway modulators | WNT1, WNT3A, WNT3 | KDM1A 4532/4885MAOB 3382/4885MAP4K4 437/4885 |
| US-10870653-B2 | WNT pathway modulators | WNT1, WNT3A, WNT3 | KDM1A 4263/4885MAOB 3029/4885MAP4K4 914/4885 |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | KDM1A 3768/4885MAOB 1751/4885MAP4K4 2438/4885 |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | KDM1A 1205/4885MAOB 931/4885MAP4K4 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.